The French company has taken a look at its R&D portfolio, and made some radical changes in oncology and diabetes.
Biopharma companies put the brakes on product deals last year, with the drop driven by a decline in oncology transactions. Meanwhile, a look at the big spenders shows how…
Pfizer is said to be interested in Amarin, but the Danish group’s need for a growth injection is greater.
As the curtain came down on a quarter many in biotech would rather forget, big pharma groups stood out by being the least bad investment option.
Vantage takes a look at the sellside’s naughty and nice list for 2018: prospects improved considerably for Merck & Co’s Keytruda and Abbvie’s Mavyret, the latter…
Novo Nordisk’s first cardiovascular collaboration could lead to an antibody versus antisense showdown in dyslipidaemia.
Novo Nordisk is determined to dominate obesity, but two discontinuations hint that the ride might be rocky.
Gelesis’s weight-loss capsule only hit one of the two co-primary endpoints in its approval trial. Will the FDA be persuaded?
The final month of 2018 will see FDA verdicts on Roche’s bid to play in the first-line lung cancer space, and what Jazz hopes will be its next big narcolepsy product.